Series B

Axion BioSystems' strategic purchase of CytoTronics brings Harvard-developed HD-MEA technology to market, promising to revolutionize disease research.

An investigational drug from Veloxis Pharmaceuticals has received a key FDA designation, offering new hope for liver transplant patients facing lifelong toxic therapies.

With healthcare costs surging, Benepass's new funding will expand its platform to give employers greater control and employees more choice in benefits.

The Drug Information Association's new platform aims to help startups overcome funding and regulatory hurdles, connecting them to investors and experts.

A new, self-administered RNA therapy for hereditary angioedema gains EU approval, promising fewer attacks and greater freedom for thousands of patients.

Centrical's new AI Role-Play platform offers realistic practice to boost employee skills, promising to slash training time and improve key business metrics.

Wendel Investment Managers' affiliates raise over €11 billion, validating the firm's strategic pivot and defying a tough private capital market.

Amid a rebounding SPAC market, FG Imperii Acquisition Corp. launches a $200M IPO, targeting North America's financial services sector with a veteran team.

With a new CRO known for driving acquisitions and IPOs, RunSafe Security aims to dominate the critical infrastructure protection market amid rising threats.

Biotech veteran Kamran Tavangar, who built a multi-billion dollar company at LabCentral, returns to lead its science strategy and shape the future of innovation.

Belgian biotech MRM Health gets the green light for a Phase 2b trial of MH002, a novel 'living drug' aimed at revolutionizing ulcerative colitis care.

A new campaign says indecision is the biggest business risk. Aily Labs' AI platform promises to end analysis paralysis and force confident, fast action.

Record AI mega-deals redefine healthcare innovation, yet a broader market contraction creates a new divide for startups and traditional medical sectors.

Prenetics slashed future dilution risk by exchanging 4.7M warrants, a move analysts see as crucial for fueling the rapid growth of its IM8 wellness brand.

Abingworth elevates Bali Muralidhar and hires Travis Wilson, signaling a major push into clinical co-development and buyouts under Carlyle's wing.

With a new growth chief and key cloud partnerships, Atropos Health is aggressively moving to make its AI the new standard for real-world evidence in medicine.

Facing soaring demand, AI robotics firm TechForce is seeking a global manufacturing partner, signaling a major shift from pilot programs to mass production.

The AI investment frenzy is shifting from GPUs to the physical world of power, cooling, and real estate, creating a new class of high-value companies.

As the year-long TRANSFORMERS crossover ends, we analyze the strategy, tech, and financial impact of a new benchmark in mobile gaming partnerships.

Beyond services, Charles River is building an ecosystem. We look at how its incubator nurtures startups and secures its own future in advanced medicine.